We are thrilled to be working on yet another innovation project – industry leaders Porvair (UK) are teaming up with Suzhou Tianlong Bio Technology Co Ltd (China), alongside Swansea Univeristy and Xi’an Jiaotong University. The collaborative project titled , “Automating & Stratification of Epigenetics in Healthcare” is an Innovate UK Jiangsu Industrial Challenge Programme.
The project will integrate Porvair’s leading brand chromatin immunoprecipitation platform, Chromatrap® with Tianlong’s expertise in automated robotic technologies and diagnostic multiplex PCR kits to develop innovative technologies in epigenetic characterisation for patient stratification in renowned precision medicine. Academics in cancer epigenetics from Swansea University and Xi’an Jiaotong University will support the project by providing insights and direction for the application in cancer research and drug development.
Developing new technologies to simplify and advance epigenetics research is the driving force here at Porvair. Combining Chromatrap with Tianlong’s expertise in diagnostic multiplex arrays, we will provide a streamlined workflow across both research and clinical applications. The ultimate collaborative goal is to provide innovative tools that improve diagnostic options for patients and informed novel stratified therapeutics.
Dr. Amy Beynon, Technical and Business Development Manager (Porvair)
The project provides an excellent opportunity for Porvair and Tianlong to develop an automated ChIP assay that enables users to perform chromatin isolation straight through to multiplex PCR, completely hands-free. This will allow researchers and diagnostic laboratories to simultaneously analyse multiple epigenetic marks using less material and enable better quantitative analysis. Availability of such technology is becoming increasingly important with the emergence of multi-marker disease diagnosis and monitoring.
Chromatrap, is a disruptive chromatin immunoprecipitation (ChIP) platform, free from beads that is taking the ChIP market by storm by replacing older bead-based technologies. With their solid state technology at the heart of every ChIP kit, Chromatrap offers users a faster, easier and far more sensitive workflow. Notably, Chromatrap eliminates laborious and time-consuming manual handling steps and with their ability to perform high throughput, Chromatrap are excited to extend their user benefits to the upcoming automated platform.
The opportunity to be the first to provide fundamental technologies for precision medicine, starting with breast and ovarian cancer, we can begin to shed light on the underlying epigenetics processes in cancer biology and take the first steps in developing therapeutics solutions for patients.
Dr. Lindsay Parkes, Senior Research Scientist (Porvair)
While diagnostic multiplex arrays are available for a number of cancer disease states, it’s availability for breast and ovarian cancers is non-existent thus impacting the development of novel therapeutics. With cancer expecting to increase by 68% by 2030*, there will be demand for personalized treatments. The project will create an epigenetics characterization toolbox that empowers researchers and diagnostic labs to further advance epigenetics research and drug development for these cancers.
*(2017), Cancer Research UK, cancerresearchuk.org
Porvair are delighted to work on a disruptive project that combines our expertise in filtration and separation technologies with a leading high throughput platform to deliver innovations and advancements in epigenetic characterizations.
Discover the many ways the Chromatrap ChIP kits can help with your own epigenetics innovation – find out which is the right kit for you with our step-by-step guide, or get in touch with our team to discuss the specific requirements of your epigenetics research.
